Literature DB >> 2215606

Ulcerative colitis and colorectal cancer. A population-based study.

A Ekbom1, C Helmick, M Zack, H O Adami.   

Abstract

BACKGROUND: The risk of colorectal cancer is increased among patients with ulcerative colitis. The magnitude of this increase in risk and the effects of the length of follow-up, the extent of disease at diagnosis, and age at diagnosis vary substantially in different studies.
METHODS: To provide accurate estimates of the risk of colorectal cancer among patients with ulcerative colitis, we studied a population-based cohort of 3117 patients given a diagnosis of ulcerative colitis from 1922 through 1983 who were followed up through 1984.
RESULTS: Ninety-two cases of colorectal cancer occurred in 91 patients. As compared with the expected incidence, the incidence of colorectal cancer in the cohort was increased (standardized incidence ratio [ratio of observed to expected cases] = 5.7; 95 percent confidence interval, 4.6 to 7.0). Less extensive disease at diagnosis was associated with a lower risk; for patients with ulcerative proctitis, the standardized incidence ratio was 1.7 (95 percent confidence interval, 0.8 to 3.2); for those with left-sided colitis, 2.8 (95 percent confidence interval, 1.6 to 4.4); and for those with pancolitis (extensive colitis, or inflammation of the entire colon), 14.8 (95 percent confidence interval, 11.4 to 18.9). Age at diagnosis and the extent of disease at diagnosis were strong and independent risk factors for colorectal cancer. For each increase in age group at diagnosis (less than 15 years, 15 to 29 years, 30 to 39 years, 40 to 49 years, 50 to 59 years, and greater than or equal to 60 years), the relative risk of colorectal cancer, adjusted for the extent of disease at diagnosis, decreased by about half (adjusted standardized incidence ratio = 0.51; 95 percent confidence interval, 0.46 to 0.56). The absolute risk of colorectal cancer 35 years after diagnosis was 30 percent for patients with pancolitis at diagnosis and 40 percent for those given this diagnosis at less than 15 years of age.
CONCLUSIONS: Close surveillance and perhaps even prophylactic proctocolectomy should be recommended for patients given a diagnosis of pancolitis, especially those who are less than 15 years of age at diagnosis.

Entities:  

Mesh:

Year:  1990        PMID: 2215606     DOI: 10.1056/NEJM199011013231802

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  457 in total

1.  Genetic instability and the mutator phenotype. Studies in ulcerative colitis.

Authors:  K R Loeb; L A Loeb
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  Increased colonic ornithine decarboxylase activity in inflammatory bowel disease in children.

Authors:  R B Pillai; V Tolia; R Rabah; P M Simpson; R Vijesurier; C H Lin
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

3.  Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low.

Authors:  R J Farrell; Y Ang; P Kileen; D S O'Briain; D Kelleher; P W Keeling; D G Weir
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

Review 4.  Cancer surveillance in inflammatory bowel disease.

Authors:  C N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  1999-12

5.  The anti-apoptotic effect of leukotriene D4 involves the prevention of caspase 8 activation and Bid cleavage.

Authors:  Katarina Wikström; Maria Juhas; Anita Sjölander
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

Review 6.  Management of Ulcerative Colitis in the Elderly.

Authors:  Manish P Shrestha; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

Review 7.  Regulation of inflammation by microbiota interactions with the host.

Authors:  J Magarian Blander; Randy S Longman; Iliyan D Iliev; Gregory F Sonnenberg; David Artis
Journal:  Nat Immunol       Date:  2017-07-19       Impact factor: 25.606

8.  Immune chaperone gp96 drives the contributions of macrophages to inflammatory colon tumorigenesis.

Authors:  Crystal Morales; Saleh Rachidi; Feng Hong; Shaoli Sun; Xinshou Ouyang; Caroline Wallace; Yongliang Zhang; Elizabeth Garret-Mayer; Jennifer Wu; Bei Liu; Zihai Li
Journal:  Cancer Res       Date:  2013-12-09       Impact factor: 12.701

Review 9.  Has the risk of colorectal cancer in inflammatory bowel disease decreased?

Authors:  Nynne Nyboe Andersen; Tine Jess
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

10.  Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions.

Authors:  Joel Pekow; Urszula Dougherty; Yong Huang; Edward Gometz; Jeff Nathanson; Greg Cohen; Shawn Levy; Masha Kocherginsky; Nanda Venu; Maria Westerhoff; John Hart; Amy E Noffsinger; Stephen B Hanauer; Roger D Hurst; Alessandro Fichera; Loren J Joseph; Qiang Liu; Marc Bissonnette
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.